This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

European Stroke Prevention Study 2

Authoring team

Evidence relating to the use of dipyridamole M/R accrues from the European Stroke Prevention Study 2 (ESPS2).

This randomised placebo-controlled trial demonstrated that the combination of dipyridamole M/R and aspirin had a small but significant added benefit over either dipyridamole M/R or aspirin alone in the scondary prevention of stroke with only a slight increase in adverse effects:

  • strokes with combination 9.5% versus aspirin 12.5%; P<0.001; NNT = 34
  • however there was no statistically significant reduction in death from all causes, and the combined endpoint of stroke and/or death was no quite significant (P=0.056) with the combination compared with aspirin.

Comparing dipyridamole M/R to aspirin alone there was no significant difference between therapies.

Adverse effects - bleeding episodes were significantly more serious and frequent in the aspirin containing groups.

Reference:

  1. MTRAC (October 1998), Summary Sheet for; Dipyridamole M/R +/- aspirin.
  2. Diener et al. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996 Nov;143(1-2):1-13.

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.